Inovio Pharmaceuticals Inc. (NASDAQ: INO) Working on a Zika Vaccine
SAN DIEGO, CA / ACCESSWIRE / February 9, 2016 / Inovio Pharmaceuticals Inc. (NASDAQ: INO) a developer of deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases, recently surged on news of the company working on a Zika vaccine. The global epidemic has sparked a new demand for pharmaceuticals to enter. Inovio is one such company that is working on developing a vaccine for the disease. However, the vaccines could be as long as years away. Before the vaccine can be administered to patients, it must first be developed and then tested. This is a time consuming process for the company and a long wait for investors to reap those rewards.
For a more detailed research report with analyst comments on Inovio Pharmaceuticals Inc. please follow the link. There is no cost obligation required to view analyst brief: http://bit.ly/1SWPk0Y-INOReport.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Small Cap Street this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. The subject Company has not compensated Small Cap Street or Robert Borowski for the creation or dissemination of this report. Small Cap Street is the party responsible for issuing the press release and for hosting the full analyst report on Small Cap Street website. Robert Borowski is the author of research report. This information is submitted to increase awareness for the Small Cap Street brand to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@SmallCapStreet.com. For any urgent concerns or inquiries, please contact us at admin@SmallCapStreet.com.
NOT FINANCIAL ADVICE:
Small Cap Street makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED:
Small Cap Street is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street has compensated Robert Borowski, up to two hundred fifty dollars for the distribution rights to disseminate analyst report. No liability is accepted by Small Cap Street whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE: Small Cap Street